Registry of Pulmonary Arterial Hypertension Linked to Connective Tissue Diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The RECONNECTIVE Registry is an observational study that focuses on patients with precapillary pulmonary hypertension associated with connective tissue diseases. It aims to gather data on clinical outcomes and the natural history of this condition over a five-year follow-up period. Patients will undergo hemodynamic confirmation through right heart catheterization to ensure accurate diagnosis and monitoring. The registry seeks to improve medical care and treatment strategies for this specific subgroup of patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Incident and prevalent patients diagnosed with Group I associated with Connective Tissue Diseases (CTD)
* Incident and prevalent patients diagnosed with Group IV Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) with evidence of a chronic thromboembolic pulmonary disease by ventilation/perfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy.
* Patient diagnosed with a connective tissue disease according to the classification criteria of the American College of Rheumatology.
* Precapillary pulmonary hypertension confirmed by right heart catheterization (RHC): Mean pulmonary arterial pressure (mPAP) \>20 mm Hg with a pulmonary arterial wedge pressure ≤ 15 mm Hg and Pulmonary vascular resistance (PVR) ≥ 2.0 Wood units

Exclusion Criteria:

* Patients who meet the criteria for another group of pulmonary hypertension (Groups II, III or V).

Where it's running

• Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
  Mexico City, Mexico Recruiting

Study contacts

• Principal investigator: Jose Luis Hernandez Oropeza, PhD — Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
• Study coordinator: Jose Luis Hernandez Oropeza, PhD
• Email: elinternista@hotmail.com
• Phone: +52 55 5487 0900

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using 129Xe MRI to Diagnose and Monitor Pulmonary Arterial Hypertension

  This study is testing if a special type of MRI can help doctors spot different types of Pulmonary Arterial Hypertension and track how the disease changes over time in people with this condition.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT06104228

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy

  This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.

  Recruiting at 3 sites Phase 4 Merck Sharp & Dohme LLC · Hyderabad, Andhra Pradesh and 2 other locations · NCT07600723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.